Summary
Unverifiable alignment: no FDA-approved labeling text was provided, so claims cannot be supported, contradicted, or assessed for omissions relative to the Cosentyx label.
Category Scores
Accurate Statements
Unsupported Statements
Cosentyx is a biologic medication.
No FDA label text was provided to support or verify the claim.
Cosentyx is a human interleukin-17A antagonist.
No FDA label text was provided to support or verify the claim.
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis.
No FDA label text was provided to support or verify the claim.
Cosentyx is indicated for the treatment of psoriatic arthritis.
No FDA label text was provided to support or verify the claim.
Cosentyx is indicated for the treatment of ankylosing spondylitis.
No FDA label text was provided to support or verify the claim.
Cosentyx works by blocking the action of interleukin-17A.
No FDA label text was provided to support or verify the claim.
Cosentyx is protected by patents that prevent generic versions from entering the market.
No FDA label text was provided to support or verify the claim.
The original patent for Cosentyx was filed in 2005 and granted in 2011.
No FDA label text was provided to support or verify the claim.
The Cosentyx patent is set to expire in 2028.
No FDA label text was provided to support or verify the claim.
Generic versions of Cosentyx will not be available until the original patent expires in 2028.
No FDA label text was provided to support or verify the claim.
The delay in generic availability for biologic medications like Cosentyx is attributed to the complex manufacturing process.
No FDA label text was provided to support or verify the claim.
Biologics are produced through living cells, making it challenging to replicate the exact same molecule.
No FDA label text was provided to support or verify the claim.
The FDA requires biologics to undergo rigorous testing and approval processes.
No FDA label text was provided to support or verify the claim.
The FDA approval process for biologics can take several years.
No FDA label text was provided to support or verify the claim.
The lack of generic availability for Cosentyx means patients may continue to rely on the branded medication.
No FDA label text was provided to support or verify the claim.
Cosentyx is often covered by insurance plans and patient assistance programs.
No FDA label text was provided to support or verify the claim.
A study found that the average annual cost of Cosentyx is around $30,000 per patient.
No FDA label text was provided to support or verify the claim.
Contradictions
Important Omissions
FDA-approved Cosentyx Prescribing Information text (e.g., boxed warning, contraindications, warnings/precautions, indications and usage, dosing/administration, adverse reactions, monitoring, drug interactions, storage/handling, and specific population labeling).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Because no FDA labeling was provided, accuracy of safety-relevant label content (contraindications, boxed warnings, warnings/precautions, dosing, monitoring, and interactions) cannot be assessed. This creates a high risk of misalignment with label-required safety information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Auditable
Primary Issue
No FDA-approved label text was supplied, so claim-to-label verification is impossible.
Suggested Improvement
Provide the FDA-approved Cosentyx Prescribing Information (full text or at least the relevant label sections: Indications and Usage; Dosage and Administration; Contraindications; Warnings and Precautions/Boxed Warning; Adverse Reactions; Drug Interactions; Use in Specific Populations; and any monitoring/storage instructions) so claims can be supported, contradicted, or assessed for omissions.